Adult Dosing
Iron deficiency anemia in patients with CKD
- Initial dose: 510 mg IV administered at a rate of up to 1 mL/sec (30 mg/sec)
- Second dose: 510 mg IV 3-8 days after the first dose
- May repeat the course after 1 month following the second injection in patients with persistent or recurrent iron deficiency anemia
Notes:- Dosage is expressed in terms of mg of elemental iron; 1 mL contains 30 mg elemental iron
- Administer as an undiluted IV injection
Pediatric Dosing
- Safety and effectiveness in pediatric patients have not been established
[Outline]
See Supplemental Patient Information
- Serious hypersensitivity reactions, including life-threatening and fatal anaphylactic-type reactions, may occur in patients receiving ferumoxytol. Monitor for signs and symptoms of hypersensitivity during and after ferumoxytol administration for at least 30 minutes and until clinically stable following completion of each administration
- Administer the drug only when emergency medical personnel and appropriate therapy measures are readily available for the treatment of anaphylaxis and other hypersensitivity reactions
- Ferumoxytol may cause clinically significant hypotension. Observe patients for signs and symptoms of hypotension following each administration of ferumoxytol
- Regularly monitor the hematologic response during parenteral iron therapy, as excessive therapy with parenteral iron can lead to excess storage of iron with the possibility of iatrogenic hemosiderosis. Do not administer to patients with iron overload
- Therapy may transiently affect the diagnostic ability of magnetic resonance imaging (MRI); alteration of MRI studies may persist for up to 3 months following the last ferumoxytol dose. Conduct MRI studies prior to therapy administration. Therapy will not interfere with X-ray, CT, PET, SPECT, ultrasound or nuclear medicine imaging
Caution: Use cautiously in
Supplemental Patient Information
- Advise patients to promptly report any signs and symptoms of hypersensitivity that may develop during and following ferumoxytol administration
- Inform patients of the risks associated with ferumoxytol therapy
- Instruct patients to report any previous history of reactions to parenteral iron products
Pregnancy Category:C
Breastfeeding: It is unknown whether ferumoxytol is excreted in breastmilk. As many drugs are excreted in human milk and because of the potential for serious adverse reactions in nursing infants, manufacturer recommends to discontinue nursing or to discontinue the drug, analyzing the importance of the drug to the mother.
